Adbry targets interleukin-13 in moderate-to-severe atopic dermatitis. Its syringe and autoinjector presentations have age-specific instructions, so the device choice cannot be separated from the patient's prescribed treatment plan.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | tralokinumab-ldrm |
| Medicine class | Interleukin-13 antagonist monoclonal antibody |
| Forms and strengths | Subcutaneous injection: 150 mg/mL single-dose prefilled syringe; 300 mg/2 mL single-dose autoinjector, with age-specific device instructions |
A specific atopic-dermatitis indication
Adbry is US-labeled for moderate-to-severe atopic dermatitis in adults and children aged 12 and older when topical prescription treatments are insufficient or inadvisable. It may be used with or without topical corticosteroids. Its interleukin-13 target does not establish indications for other allergic or inflammatory conditions.
Source: [1]
Device and age qualifications
The label lists a 150 mg/mL prefilled syringe and a 300 mg/2 mL autoinjector. Adult instructions include both presentations; the pediatric regimen uses the syringe and the autoinjector is not intended for patients younger than 18. Treatment includes a distinct loading phase. The number of devices must match the prescribed amount, not a guess from pack size.
Source: [1]
Eye symptoms and hypersensitivity
Conjunctivitis and keratitis are important warnings. New or worsening eye symptoms should be reported to the treating team. Hypersensitivity, including anaphylaxis and angioedema, can occur; severe reactions need immediate medical care. Injection-site reactions and upper respiratory infections are also reported adverse effects in the label.
Source: [1]
Vaccination and helminth precautions
Complete age-appropriate vaccinations before treatment as advised by the clinical team and avoid live vaccines during use. Treat pre-existing helminth infections before starting. Infection that does not respond to appropriate antiparasitic treatment may require a clinician-directed interruption. These precautions should be reviewed before injections begin, not inferred from a comparison page.
Source: [1]
Keep loading and maintenance instructions separate
Adbry is injected under the skin after training. Adults and adolescents have different regimens, and selected adult maintenance changes require a clinical decision. Record the device and treatment phase clearly. Do not transfer Dupixent's wider indication list, age thresholds or schedules to tralokinumab.
The Dupixent and Adbry comparison provides a separate side-by-side reference, without establishing an individual treatment choice.
Source: [1]
Questions and answers
Does Adbry have the same indication range as Dupixent?
No. The cited Adbry label is for qualified moderate-to-severe atopic dermatitis, not the full range of another biologic's uses.
Can an adolescent use the Adbry autoinjector instead of the syringe?
The cited autoinjector instructions are for adults; pediatric treatment uses the syringe regimen.
Why discuss vaccines before starting Adbry?
The label calls for vaccination review before initiation and avoidance of live vaccines during treatment.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026